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Abstract: Magnesium (Mg2+) is an enzyme co-factor that plays a key role in many biochemical 
reactions, as well as in glucose metabolism. Clinical evidences have demonstrated that depletion of 
serum Mg2+ increases exponentially with the duration of type 2 diabetes mellitus (T2DM). Diabetes 
is associated with low Mg2+, and hypomagnesemia is associated with insulin resistance, 
inflammation, and increased risk for cardiovascular disease. In subjects at high risk of 
inflammation and insulin resistance, supplementation of Mg2+ alone ameliorates both phenotypes, 
slowing the development and progression of hepatic steatosis. We analyze the relationship 
between serum Mg2+ levels and the onset of T2DM in a large cohort of well-characterized adult 
white individuals participating in the CATAMERI study, who were reexamined after a mean 
follow-up of 5.6 ± 0.9 years. In our analysis we acquired a significant negative correlation between 
Mg2+ levels, fasting glucose, and 2h-post load glucose in subjects who underwent an OGTT. 
Moreover, Mg2+ levels correlated negatively with fasting insulin levels, and positively with the 
lipid profile. As for the detrimental effect of lower circulating Mg2+ levels, our data revealed a 
significant reduction of T2DM risk of about 20% for each 1 mg/dL increase of circulating Mg2+. The 
present results are consistent with the theory that Mg2+ supplementation could ameliorate insulin 
sensitivity reducing the risk to develop T2DM. 
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1. Introduction 
Mg2+ is one of the most abundant elements in nature, and its importance for human health has 
been recognized since the early 1900s [1]. In average, each person carries approximately 24 g (1 mol) 
of Mg2+, which is mainly stored in the bones and within the cells. Its homeostasis is only marginally 
affected by hormonal regulation, and Mg2+ levels in the blood strongly depend on the dynamic 
balance between intestinal absorption and renal excretion, whereas only about one third of the bone 
reservoir is exchangeable [2]. Nonetheless, the circulating concentration of Mg2+ is tightly controlled 
(range 0.9–1.0 mM), 70–80% of total Mg2+ circulates in the biologically active ionized (free) form, 
while the residual portion is bound to carrier proteins (e.g., albumin) (20–30%) or anions (e.g., 
phosphate, citrate, bicarbonate) (1–2%) [3,4]. Dietary intake of Mg2+ through food is generally 
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considered sufficient to satisfy the recommended daily allowance of 420 mg for men and 320 mg for 
women [5]. 
Mg2+ is an enzyme co-factor in many biochemical reactions, regulating a number of 
physiological functions such as muscle contraction, neuromuscular conduction, glycemic control, 
myocardial electrical activity, and blood pressure [6–8]. Moreover, at a molecular level, Mg2+ is 
required by all enzymes involved in phosphorylation/dephosphorylation processes, which are 
usually pivotal for the transduction of intracellular signaling involving cell survival and metabolism 
[3,9]. Hypomagnesemia is clinically defined at serum Mg2+ concentration <0.5 mM, and may be due 
to primary deficiency [3], reduced Mg2+ intake and/or increased depletion [9]. Secondary Mg2+ 
deficiency may develop as a consequence of various pathologies (e.g., diabetes mellitus type II, 
alcoholism, HIV/AIDS, acute myocardial infarction) and treatments (e.g., hypermagnesuric 
diuretics, digitalis, cardiopulmonary bypass) [10].  
Primary chronic hypomagnesemia has been linked to increased risk of preclinical and clinical 
events related to the metabolic syndrome, including: Cardiovascular disease and atherosclerosis, 
glucose intolerance, insulin resistance, diabetes mellitus, endothelial dysfunction, alterations of the 
lipid pattern, obesity, atheroma formation, platelet aggregation/abnormal thrombosis, 
inflammation, oxidative stress, and cardiovascular mortality [10–16].  
More specifically, the antiatherogenic effects of Mg2+ appear to involve the modulation of lipid 
metabolism and turnover [17–19], and in the intestinal tract, Mg2+ can form insoluble soaps with fatty 
acids and therefore prevent absorption of dietary fat [20]. Obese adults and children are chronically 
deficient in Mg2+, which may help to explain the insulin resistance observed in these patients [21,22]; 
indeed, Mg2+ plays an important role in glucose metabolism regulating insulin secretion from 
pancreatic β-cells [23], transduction of the insulin signaling, and it modulates active glucose 
transporter into peripheral tissues [24]. In subjects at high risk of inflammation and insulin 
resistance, supplementation of Mg2+ alone ameliorates both phenotypes [25,26], slowing the 
development and progression of hepatic steatosis [27].  
Consistent with these evidences, in 2005 a meta-analysis showed that the risk of T2DM was 
increased across all studies in subjects in the lowest Mg2+ consumption category [15], and that the 
risk was 8–13% lower per 100 mg/day increment in Mg2+ intake. To the best of our knowledge, only 
very few longitudinal epidemiological studies have analyzed the impact of serum Mg2+ levels on the 
risk of developing T2DM, and most of them appear inconsistent and inconclusive. 
For this reason, in the present study, we point to analyze the relationship between serum Mg2+ 
levels and the onset of T2DM in a large cohort of well-characterized adult white individuals 
participating in the CATAnzaro MEtabolic RIsk factors study (CATAMERIS), who were reexamined 
after a mean follow-up of 5.6 ± 0.9 years. 
2. Materials and Methods  
2.1. Study Population 
The study group consisted of 589 white Caucasian subjects (288 men and 301 women), enrolled 
in the CATAMERIS, an observational study assessing cardio-metabolic risk in individuals carrying 
at least one risk factor including overweight/obesity, hypertension, dyslipidemia, dysglycemia, and 
family history for T2DM. The CATAMERI study is a metabolic disease prevention campaign 
dedicated to the identification and characterization of cardio-metabolic risk factors [28,29]. At the 
baseline, subjects, aged 21–75 years (mean 47 ± 13), were excluded if they had a history of 
cardiovascular disease, chronic gastrointestinal diseases, chronic pancreatitis, history of any 
malignant disease, history of alcohol or drug abuse, liver or kidney failure and treatments able to 
modulate glucose metabolism, including hypoglycemic agents. All subjects were subjected to 
anthropometrical evaluation before undergoing an oral glucose tolerance test (OGTT): Weight, 
height, body mass index (BMI), and waist circumference (WC) were measured, and body 
composition was evaluated by bioelectrical impedance. After a 12-h fast, a 75-g OGTT was 
performed with 0, 30, 60, and 120 min sampling for plasma glucose and insulin levels 
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measurements. In accordance to the American Diabetes Association (ADA) criteria [30], subjects 
were classified into three groups according to the glucose tolerance status as having normal glucose 
tolerance (NGT) when fasting plasma glucose (FPG) was <7.0 mmol/L (100 mg/dL) and 2-h post-load 
<7.8 mmol/L (140 mg/dL), impaired fasting glucose (IFG) when FPG was 5.6–6.9 mmol/L (100–125 
mg/dL) and 2-h post-load <7.8 mmol/L (140 mg/dL), impaired glucose tolerance (IGT) when FPG 
was <5.6 mmol/L (100 mg/dL) and 2-h post-load was 7.8–11.0 mmol/L (140–199 mg/dL) and diabetes 
when FPG was > 7.0 mmol/L (126 mg/dL) and/or 2-h plasma glucose > 11.1 mmol/L (200 mg/dL).  
For longitudinal study analysis, non-diabetic subjects who completed the baseline 
measurements were invited to a follow-up (FU) visit, or contacted by a telephonic survey, in order to 
evaluate their metabolic condition and to establish the time of the onset of T2DM. The study was 
approved by local Institutional Ethics Committees of University "Magna Graecia" of Catanzaro 
(approval code: 2012.63). Written informed consent was obtained from each subject in accordance 
with principles of the Declaration of Helsinki. 
2.2. Calculation 
Two indexes of insulin secretion were calculated from the OGTT data using the Stumvoll index 
(first-phase secretion = 1283 + 1.829 × Ins30 − 138.7 × Gluc30 + 3.772 × Ins0) [31], where Ins is insulin 
and Gluc is glucose, and early-phase insulin secretion was assessed by the ratio of insulin AUC0-30 
to glucose AUC0-30 (InsAUC30/GluAUC30) during the OGTT [32]. The estimated glomerular 
filtration rate (e-GFR) was calculated by using the CKD-EPI equation [33]: eGFR = 141 xmin(Scr/k, 
1) xmax(Scr/k, 1) − 1.209 × 0.993Age × 1.018 (if female), where Scr is serum creatinine, k is 0.7 for 
females and 0.9 for males,  is − 0.329 for females and − 0.411 for males, min indicates the minimum 
of Scr/k or 1, and max indicates the maximum of (Scr/k or 1). Insulin sensitivity was evaluated using 
the Matsuda Index (insulin sensitivity index, ISI) calculated as follows: 10,000/square root of (fasting 
glucose (mmol/L) × fasting insulin (mU/L)) × (mean glucose × mean insulin during OGTT). The 
homeostasis model assessment (HOMA) index was calculated as fasting insulin × fasting 
glucose/22.5 [34]. 
2.3. Laboratory Determinations 
HbA1c was measured with high performance liquid chromatography using a National 
Glycohemoglobin Standardization Program (NGSP) certified automated analyzer (Adams HA-8160 
HbA1C analyzer, Menarini, Italy). Glucose, triglycerides, total, and high-density lipoprotein (HDL) 
cholesterol concentrations were determined by enzymatic methods (Roche, Basel, Switzerland). 
Plasma glucose was measured by the glucose oxidation method (Beckman Glucose Analyzer II; 
Beckman Instruments, Milan, Italy). Triglycerides and total and HDL cholesterol concentrations 
were measured by enzymatic methods (Roche Diagnostics, Mannheim, Germany). Plasma insulin 
concentration was determined by a chemiluminescence-based assay (Roche Diagnostics). Plasma 
insulin concentration was measured with a chemiluminescence-based assay (Immulite®, Siemens, 
Italy). Serum Mg2+ concentrations were measured by COBAS INTEGRA Magnesium, based on the 
colorimetric method assay (Roche Diagnostic, Mannheim, Germany). 
2.4. Statistical Analysis 
The results for continuous variables are given as means ± SD. Anthropometric and metabolic 
differences between groups were tested after adjusting for age, and gender using a general linear 
model with post hoc Bonferroni correction for multiple comparisons. The X2 test was used for 
categorical variables. Variables with skewed distribution (i.e., triglycerides, fasting insulin, HOMA 
index, and InsAUC30/GluAUC30) were log transformed to meet the normality assumption for 
statistical purposes. Correlation coefficients were calculated according to Pearson’s method. Partial 
correlation coefficients adjusted for age, sex, and BMI, were computed between variables. A multiple 
Cox regression analysis including age, sex, and BMI at the baseline as covariates was used to 
determine the association between the study groups and the risk to develop T2DM. For all analyses, 
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p ≤ 0.05 was considered to be statistically significant. All analyses were performed using the 
statistical package SPSS 22.0 for Windows (SPSS, Chicago, IL, USA). 
3. Results 
Table 1 represents the anthropometric, biochemical, and metabolic characteristics of subjects 
stratified according to ADA criteria for the classification of glucose tolerance [30]. No significant 
differences between the three study groups were observed with respect to gender (p = 0.62). As 
reported in Table 1, the subjects in the NGT group were younger (p < 0.0001 versus IFG/IGT and 
T2DM) and showed a significantly better profile for metabolic parameters, such as FPG (p < 0.0001 
versus IFG/IGT and T2DM), 2-h post load plasma glucose (p < 0.0001 versus IFG/IGT and T2DM), 
insulin levels (p < 0.001 versus IFG/IGT and p < 0.0001 versus T2DM), HbA1c% (p < 0.001 versus 
IFG/IGT and p < 0.0001 versus T2DM), HOMA-IR and Matsuda Index (each with p < 0.0001 versus 
IFG/IGT and T2DM), after adjusting for age, sex, and BMI. Circulating Mg2+ levels were significantly 
lower in the T2DM group (p < 0.01 versus NGT and p < 0.02 versus IFG/IGT). No significant 
differences were reported for the lipid profile even though triglycerides were significantly increased 
in IFG/IGT (p < 0.01) and newly diagnosed T2DM groups (p < 0.001). SBP appeared significantly 
better in the NGT group (p < 0.01 versus IFG/IGT and T2DM) and no difference was found for DBP 
values (p = 0.06). Finally, the InsAUC30/GluAUC30 and the Stumvoll first-phase indexes of insulin 
secretion, estimated from the OGTT, showed differences among the three groups of individuals. In 
detail, the NGT group had a better b-cell function with respect to IFG/IGT and T2D when the 
Stumvoll first-phase index (p < 0.05 and p < 0.01, respectively) and InsAUC30/GluAUC30 (p < 0.01 
and p < 0.01, respectively) were analyzed (Table 1). 
Table 1. Anthropometric and metabolic characteristics of the study subjects stratified according to 
American Diabetes Association (ADA) criteria for the classification of glucose tolerance. 
Variables 
Whole 
Study 
Group 
NGT (1) IFG/IGT (2) T2D (3) p 
p p p 
(1 vs. 2) (1 vs. 3) (2 vs. 3) 
Gender (M/F) 288/301 146/207 108/77 34/17 0.62 — — — 
Age (years) 47 (±13) 44 (±14) 51 (±11) 55 (±12) 
<0.0001 
* 
<0.0001 <0.0001 <0.04 
BMI (Kg/m2) 30.7 (±7.1) 30.1 (±7.2) 31.5 (±6.9) 31.8 (±6.9) <0.001 ** <0.001 <0.01 0.47 
SBP (mmHg) 124.4 (±16.1) 120.9 (±15.1) 128.7 (±15.8) 132.4 (±17.2) <0.01 <0.01 <0.01 0.41 
DBP (mmHg) 77.5 (±10.3) 76.4 (±10.4) 78.4 (±9.6) 81.5 (±11.3) 0.06 0.28 <0.03 0.11 
Tot-COL (mg/dL) 195.2 (±40.6) 193.0 (±39.6) 199.7 (±37.0) 193.9 (±56.1) 0.24 0.10 0.94 0.36 
HDL-Col (mg/dL) 50.8 (±14.1) 53.1 (±13.9) 48.0 (±13.9) 45.6 (±13.2) <0.01 <0.01 <0.02 0.41 
LDL-Col (mg/dL) 123.9 (±35.4) 121.7 (±35.2) 128.3 (±31.2) 123.4 (±48.2) 0.33 0.18 0.84 0.31 
Triglycerides (mg/dL) 127.6 (±77.0) 113.1 (±68.4) 144.3 (±80.7) 169.4 (±92.3) <0.001 <0.01 <0.001 0.07 
Mg2+ (mg/dL) 1.99 (±0.18) 2.01 (±0.17) 1.99 (±0.18) 1.92 (±0.21) <0.02 0.66 <0.01 <0.01 
HbA1c (%) 5.60 (±0.67) 5.38 (±0.32) 5.65 (±0.37) 6.94 (±1.39) <0.0001 <0.001 <0.0001 <0.0001 
HOMA-IR 3.53 (±3.02) 2.89 (±2.07) 3.89 (±2.09) 6.69 (±7.09) <0.0001 <0.001 <0.0001 <0.0001 
e-GFR, mL/min/1.73/m2 133.8 (±38.6) 142.6 (±39.3) 122.2 (±34.2) 117.5 (±33.5) 0.84 0.71 0.75 0.59 
Fasting glucose (mg/dL) 94.4 (±13.2) 88.8 (±7.5) 100.1 (±10.9) 112.1 (±23.7) <0.0001 <0.0001 <0.0001 <0.0001 
2-h glucose (mg/dL) 127.5 (±38.4) 107.3 (±22.3) 147.3 (±24.6) 209.1 (±45.4) <0.0001 <0.0001 <0.0001 <0.0001 
FP insulin (mU/ml) 14.9 (±12.1) 13.2 (±9.4) 15.6 (±8.1) 24.1 (±28.0) <0.0001 <0.003 <0.0001 <0.0001 
Stumvoll 1st-phase Index 
1722 
(±1002.5) 
1855 
(±1034.1) 
1547 
(±939.5) 
1361 
(±782.1) 
<0.02 <0.05 <0.01 0.11 
InsAUC30/GluAUC30 8.3 (±5.7) 9.1 (±6.1) 7.1 (±4.7) 6.7 (±5.3) <0.01 <0.01 <0.01 0.26 
Matsuda Index 66.9 (±44.6) 79.9 (±47.5) 50.2 (±31.5) 31.3 (±19.1) <0.0001 <0.0001 <0.0001 <0.1 
Hypolipidemic Teraphy % 11.9 5.9 11.9 33.3 <0.0001 <0.0001 <0.0001 <0.01 
Hypertension % 52.1 41.6 65.4 76.5 <0.0001 <0.0001 <0.0001 0.13 
Diuretics % 11.9 4.2 14.6 13.7 <0.0001 <0.0001 <0.01 0.87 
Family history of diabetes 
% 
53.3 51.3 52.0 71.7 <0.03 0.92 <0.01 <0.02 
Data are means ± SD. Comparisons among the three groups were performed using a general linear model with post hoc 
Bonferroni correction for multiple comparisons. p values refer to results after analyses with adjustment for age, gender, 
and BMI. *p values refer to results after analyses with adjustment for gender and BMI. **p values refer to results after 
analyses with adjustment for age and gender. Categorical variables were compared by X2 test. IGT, impaired glucose 
tolerance; IFG, impaired fasting glucose; SBP, systolic blood pressure; DBP, diastolic blood pressure. 
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In the univariate analyses adjusted for the same covariates (Table 2), circulating Mg2+ levels 
correlated positively with Tot-Col (r = 0.151, p < 0.001), HDL-Col (r = 0.103, p < 0.01), and LDL-Col (r = 
0.164, p < 0.0001) while, more interestingly, we report a negative correlation with HbA1c (r = −0.101, p 
< 0.001), FPG (r = −0.112, p < 0.01), 2-h PG (r = −0.122, p < 0.01), and BMI (r = −0.105, p < 0.01).  
Table 2. Univariate correlations between Mg2+ levels and anthropometric and metabolic variables. 
Variables 
Pearson’s Correlation 
Coefficient (r) 
p 
Age (years) −0.066 0.107 * 
BMI (Kg/m2) −0.087 0.03 ** 
SBP (mmHg) 0.045 0.275 
DBP (mmHg) 0.048 0.248 
Tot-Col (mg/dL) 0.154 <0.001 
HDL-Col (mg/dL) 0.113 <0.01 
LDL-Col (mg/dL) 0.170 <0.001 
Triglycerides (mg/dL) 0.01 0.981 
HbA1c (%) −0.099 0.018 
Fasting glucose (mg/dL) −0.119 <0.01 
2-h glucose (mg/dL) −0.116 <0.01 
FP insulin (mU/ml) −0.073 0.08 
e-GFR, mL/min/1.73/m2 −0.036 0.41 
Adjusted for age, gender, and BMI *Adjusted for gender and BMI; **Adjusted for age and gender. 
BMI = body mass index; SBP = systolic blood pressure; DBP = diastolic blood pressure; HDL = high 
density lipoprotein; LDL = low density lipoprotein. 
To estimate the independent contribution of Mg2+, on the indices of insulin secretion (Stumvoll 
first- and InsAUC30/GluAUC30), we conducted a multivariate regression analysis in a model also 
including age, sex, BMI, systolic and diastolic blood pressure, triglycerides, total and HDL 
cholesterol (Table 3). The variables that remained significantly associated with 
InsAUC30/GluAUC30 were age (β = −0.333; p < 0.0001), BMI (β = 0.239; p < 0.0001), and Mg2+ (β = 0.08; 
p < 0.04). Similarly, when we use the Stumvoll first-phase as dependent variable in a multivariate 
regression analysis we found significantly associated the age (β = −0.309; p < 0.0001), BMI (β = 0.290; p 
< 0.0001), and Mg2+ (β = 0.108; p < 0.01). No differences were reported when dyslipidemic therapy, 
presence of hypertension, and diuretics use were included in the analysis.  
Table 3. Multiple regression analysis with indices of insulin secretion as dependent variables. 
Indices of Insulin Secretion Independent Contributors Standardized Coefficient β p 
InsAUC30/GluAUC30 * 
Age 
BMI 
Mg2+ 
−0.333 
0.239 
0.09 
<0.0001 
<0.0001 
<0.04 
Stumvoll 1st-phase Index * 
Age 
BMI 
Mg2+ 
−0.309 
0.290 
0.108 
<0.0001 
<0.0001 
<0.01 
* Model includes age, sex, BMI, systolic and diastolic blood pressure, triglycerides, total and HDL cholesterol. 
To estimate the independent contribution of Mg2+ to the risk of T2DM, we performed a logistic 
regression analysis, which is reported in Table 4. In the first model (Model 1) only age, gender, BMI, 
and Mg2+ were included as confounding variables, resulting in a nominally significant association 
with reduced odds of developing diabetes (OR = 0.844 CI 95% 0.727–0.980, p < 0.03). In Model 2, 
which additionally included the presence of family history of diabetes, hypertension, dyslipidemic 
therapy, or diuretics, Mg2+ was significantly associated with the reduced onset of T2DM (OR = 0.836 
CI 95% 0.719–0.972, p < 0.02). Since increased renal Mg2+ excretion may result from uncontrolled 
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glycemic status, therefore causing lower circulating Mg2+ levels, the subsequent analysis was 
performed in the presence of e-GFR. Both the association and its direction remained consistent with 
what was obtained in Model 2 (OR = 0.765 CI 95% 0.629–0.932, p < 0.01) (Model 3). 
Table 4. Odds ratio (95% CI) by multiple logistic regression analysis for the risk to develop T2DM. 
Study Group OR 95% CI p 
Model 1 0.844 0.727–0.980 <0.03 
Model 2 0.836 0.719–0.972 <0.02 
Model 3 0.765 0.629–0.932 <0.01 
Model 1: Adjusted for age, gender, BMI, and Mg2+; Model 2: Model 1 + family history of diabetes + 
therapies; Model 3: Model 2 + e-GFR. 
Among the whole study population, 365 non-diabetic subjects (almost 62% of the baseline 
population) were longitudinally studied over a FU period (mean FU, 5.6 ± 0.8 years) to evaluate the 
incidence of T2DM (Table 5). To estimate the hazard ratio (HR) of Mg2+ in the onset of T2DM, a Cox 
regression analysis including age, sex, BMI, glucose tolerance status, smoking habits, presence of 
hypertension, dyslipidemia, and relative treatments (i.e., diuretics and statins) has been performed. 
As indicated in Table 5, we observed an HR = 0.764 with 95% CI = 0.636–0.918 (p < 0.01) (Model 1), 
explaining the detrimental effect of low levels of circulating Mg2+. After adding to the Model 1 
therapies for hypertension, dyslipidemia, or diuretics, tolerance status at basal, the presence of a 
family history of diabetes and e-GFR, the analysis remained significant (HR = 0.790 with 95% CI = 
0.645–0.967; p = 0.022). 
Table 5. Hazard ratio (HR) (95% CI) by multiple logistic regression analysis for the risk to develop 
T2DM. 
Study Group HR 95% CI P 
Model 1 0.764 0.636–0.918 <0.01 
Model 2 0.790 0.645–0.967 0.022 
Model 1: Adjusted for age, gender, BMI, and Mg2+; Model 2: Model 1 + therapies for hypertension, 
dyslipidemia, or diuretics + tolerance status+ family history of diabetes + e-GFR. 
4. Discussion 
Mg2+ can be found in many foods such as grains, nuts, and green leafy vegetables, and it plays a 
key role in many fundamental biological processes, as well as in glucose metabolism [7]. Over the 
past two decades clinical evidence have been reported, showing that depletion of serum Mg2+ 
increases exponentially with the duration of T2DM [35]. Diabetes is associated with low Mg2+ [24], 
and hypomagnesemia is associated with insulin resistance, inflammation, and increased risk for 
cardiovascular disease [36]. 
At the molecular level, it has been suggested that hypomagnesemia may induce altered cellular 
glucose transport, defective tyrosine-kinase activity, and insulin receptor autophosphorylation, 
post-receptor impairment in insulin action by influencing intracellular signaling cascade and 
processing, reduced pancreatic insulin secretion, and worsening of insulin resistance in diabetics 
[37–40]. Above all, defective insulin receptor phosphorylation is regarded as the main mechanism by 
which hypomagnesemia contributes to insulin resistance in T2DM patients [24], and some 
epidemiological studies have suggested that adequate Mg2+ intake may reduce T2DM incidence [41]. 
On the other hand, insulin is known to stimulate the transport of Mg2+ from the extracellular to 
the intracellular compartment. Therefore, T2DM could contribute to the reduction of serum Mg2+ 
levels, and this could, in turn, worsen glycemic control of diabetes. The chronicity of this vicious 
cycle has been suggested to accelerate the impairment of metabolic control and to predispose to 
chronic complications of T2DM [36,38,42,43].  
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This project supplies evidences of this complex phenomenon. In our analysis we acquired a 
significant negative correlation between Mg2+ levels, fasting glucose, and 2h-post load glucose in 
subjects who underwent an OGTT. Moreover, Mg2+ levels correlated negatively with fasting insulin 
levels, and positively with the lipid profile. As for the detrimental effect of lower circulating Mg2+ 
levels, a Cox proportional hazard regression analysis revealed a significant reduction of T2DM risk 
of about 20% for each 1 mg/dL increase of circulating Mg2+. 
The multivariate regression analysis showed a strong and significant association between 
serum Mg2+ levels with InsAUC30/GluAUC30 and the first phase of insulin secretion for the overall 
group. It has been proposed that the decrease in insulin sensitivity precedes the impairment of b-cell 
function, and that the impairment of b-cells to compensate for insulin resistance is a late 
phenomenon [44]. 
The present study has several strengths including the large sample size and the homogeneity of 
the patient group, the detailed characterization of the study population, the centralization of 
biochemical analyses, and the exclusion of differences in dietary habits and nutritional conditions. 
Unfortunately, it was not possible to estimate the daily food and water intake in terms of Mg2+, 
during the follow-up period, but overall, during the follow-up visit, the subjects referred no 
variations in their dietary habits. 
Other solid aspects are the prolonged time of follow-up and the exclusion of residual 
confounding, although outcomes were adjusted for a wide range of potential confounders. At the 
same time, the geographical and ethnical restriction of the population should be considered as a 
limit to the generalizability of the data: All participants to the study were Caucasians from Southern 
Italy, and whether the present findings can also be extended to non-Caucasian ethnic groups will 
require extensive evaluation in the future.  
One limitation of our study is the impossibility to address the question of at what point in the 
natural history of type 2 diabetes do Mg2+ levels start to decrease. The best way to address this issue 
would probably be to compare repeated measurements of Mg2+ across a time period. In future 
research, this approach would allow grouping of similar trajectories within homogenous subgroups, 
while limiting the within-person variability. In addition to this, we acknowledge that serum Mg2+ is 
not a robust predictor of type 2 diabetes risk, and that it is possible that the small differences in 
serum Mg2+ levels observed in our cohort might be amplified in other districts (e.g., intracellular and 
interstitial compartments), but we have no information about this issue. 
The present results are consistent with the theory that Mg2+ supplementation could ameliorate 
insulin sensitivity reducing the risk to develop T2DM. Oral Mg2+ supplements appear to be useful in 
persons with T2DM to restore Mg2+ deficiencies, to improve insulin resistance, oxidative stress, and 
systemic inflammation [45]. This finding suggests the need for screening serum magnesium levels in 
the subjects in the high-risk groups for developing glucose metabolic disorders. However, the 
picture is still far from complete, and requiring confirmation by further studies to fully understand 
the complex and dynamic effect of Mg2+ in T2DM and to elucidate the role of the nutrient as a 
protector factor against metabolic disorders. 
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